GWLL GOLDENWELL BIOTECH, INC.

CIK 0001800373 8 ready 8-Ks latest August 19, 2025, 7:59 PM ET RSS · JSON

Activity: ELEVATED 2 filings / 30d vs 0 baseline Risk accumulating: auditor change (1)

Ready 8-Ks 8

Latest filing October 9, 2026, 9:50 AM ET

Top materiality 0.70

Event mix other_material ×7 · leadership ×1

Sentiment 0 pos · 3 neg · 5 neu

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for GWLL

Highest-materiality recent filing

Goldenwell Biotech dismisses BF Borgers as auditor, cites going-concern doubt in prior reports

May 20, 2024, 7:59 PM ET other material materiality 0.70 negative item 4.01 item 9.01

Dismissed BF Borgers CPA PC on May 14, 2024, following board approval.
BF Borgers' reports for FY 2022 and 2023 included substantial doubt about going concern.

August 19, 2025, 7:59 PM ET other material materiality 0.60 negative item 4.01 item 9.01 ◈ Auditor Changes ×2

Goldenwell Biotech's auditor KCCW resigns; Michael Gillespie & Associates appointed

KCCW resigned as independent registered public accounting firm on July 24, 2025, with no disagreements on accounting principles.
November 15, 2024, 6:59 PM ET other material materiality 0.60 neutral item 4.01 item 9.01 ◈ Auditor Changes ×2

Goldenwell Biotech dismisses auditor after PCAOB revokes registration; appoints new auditor

Dismissed Yusufali & Associates on Nov 13, 2024, after PCAOB revoked its registration.
May 20, 2024, 7:59 PM ET other material materiality 0.70 negative item 4.01 item 9.01

Goldenwell Biotech dismisses BF Borgers as auditor, cites going-concern doubt in prior reports

Dismissed BF Borgers CPA PC on May 14, 2024, following board approval.
September 9, 2021, 7:59 PM ET other material materiality 0.60 neutral item 4.01 item 9.01

Goldenwell Biotech dismisses auditor Gillespie & Associates, engages BF Borgers

Dismissed Michael Gillespie & Associates on Sept 8, 2021, effective immediately.

Appointed

director

GWLL · GOLDENWELL BIOTECH, INC.

On October 8, 2026, the board of directors of Goldenwell Biotech, Inc. (the “Company”) appointed Ming Zhou as a director.

Max materiality 0.70 · Median 0.57 · Most common event other_material

0 positive 3 negative 5 neutral